title: Omitting or reducing radiotherapy in childhood or adolescence Hodgkin Lymphoma.
abstract: Despite high cure rates, treatment of childhood Hodgkin Lymphoma (HL) is associated with late effects caused mainly by radiotherapy (RT). In the GPOH-HD95 trial of the German Society of Pediatric Oncology and Hematology that was recently published in the Journal of Clinical Oncology, RT was spared in patients achieving a stringently defined complete remission (CR) with chemotherapy and reduced in patients with a good partial remission (PR). Overall, RT-treated patients had superior PFS, but overall survival (OS) was almost identical within each risk-stratified treatment group irrespectively of the use of RT. In the low-risk group, RT could be safely omitted in 20% of patients. In contrast, failure rates were considered unacceptable, when RT was omitted in intermediate or high risk patients achieving a CR. However, salvage therapy was successful, equalizing overall survival between irradiated and non-irradiated patients. Although GPOH-HD95 points out to the omission of RT in selected patients achieving a CR after chemotherapy, especially those in the low-risk group, more than 80% of the patients are still irradiated. Notably, the GPOH-HD95 was not a randomized trial. In conclusion, according to the GPOH-HD95 trial, RT can be safely omitted in pediatric and adolescent patients with low-risk, early stage HL achieving a stringently defined CR after 2 cycles of OPPA or OEPA chemotherapy. RT dose could also be reduced in case of good PR by conventional imaging. However, conventional response assessment is not the optimal means to decide whether RT is needed or not. It is now increasingly recognized that RT can be omitted in many patients with HL without compromising the final outcome and it appears wise to try to stringently limit RT in those patients who really need it. This might be achieved through the use of modern functional imaging (PET/CT). Such efforts are already in progress and results regarding efficacy are awaited relatively soon.
authors.affiliation: 1 Department of Haematology, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece ; 2 Department of Pediatric Hematology-Oncology, Marianna V. Vardinoyannis-ELPIDA Children's Oncololgy Unit, Agia Sofia Children's Hospital, Athens, Greece.
authors.forename: Theodoros P
authors.initials: TP
authors.lastname: Vassilakopoulos
authors.affiliation: 1 Department of Haematology, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece ; 2 Department of Pediatric Hematology-Oncology, Marianna V. Vardinoyannis-ELPIDA Children's Oncololgy Unit, Agia Sofia Children's Hospital, Athens, Greece.
authors.forename: Georgios
authors.initials: G
authors.lastname: Boutsikas
authors.affiliation: 1 Department of Haematology, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece ; 2 Department of Pediatric Hematology-Oncology, Marianna V. Vardinoyannis-ELPIDA Children's Oncololgy Unit, Agia Sofia Children's Hospital, Athens, Greece.
authors.forename: Vassilios
authors.initials: V
authors.lastname: Papadakis
keywords: Hodgkin Lymphoma (HL); adolescents; chemotherapy; childhood; radiotherapy (RT)
references.citation: Blood. 2006 Jun 15;107(12):4636-42
references.pmid: 16478882
references.citation: Strahlenther Onkol. 2012 Aug;188(8):649-52
references.pmid: 22729282
references.citation: J Clin Oncol. 2010 Aug 10;28(23):3680-6
references.pmid: 20625128
references.citation: J Clin Oncol. 2012 Nov 1;30(31):3783-5
references.pmid: 23008306
references.citation: Oncologist. 2012;17(8):1011-3
references.pmid: 22807512
references.citation: J Clin Oncol. 2013 Apr 20;31(12):1562-8
references.pmid: 23509321
references.citation: J Clin Oncol. 2002 Sep 15;20(18):3765-71
references.pmid: 12228196
references.citation: Blood. 2012 Nov 29;120(23):4488-95
references.pmid: 22821764
references.citation: Med Pediatr Oncol. 1999 May;32(5):366-72
references.pmid: 10219339
references.citation: N Engl J Med. 2003 Jun 12;348(24):2396-406
references.pmid: 12802025
references.citation: Oncologist. 2012;17(8):1006-10
references.pmid: 22807513
references.citation: J Clin Oncol. 2011 Nov 10;29(32):4234-42
references.pmid: 21990399
references.citation: J Clin Oncol. 2012 Sep 10;30(26):3174-80
references.pmid: 22649136
references.citation: Semin Hematol. 2013 Jan;50(1):4-14
references.pmid: 23507479
references.citation: Lancet. 2012 May 12;379(9828):1791-9
references.pmid: 22480758
references.citation: N Engl J Med. 2012 Feb 2;366(5):399-408
references.pmid: 22149921
references.citation: Blood. 2012 Sep 13;120(11):2195-202
references.pmid: 22826564
references.citation: J Clin Oncol. 1999 Dec;17(12):3736-44
references.pmid: 10577845